



Society for Immunotherapy of Cancer

## Congressional Report Language

**FISCAL YEAR 2022**

### **NCI Report Language**

*Cancer Immunotherapy.*—The Committee recognizes that NCI-supported research exploring cancer immunology, cancer immunotherapy and cancer vaccines that started years before the emergence of COVID-19 contributed to the rapid development of COVID-19 treatments and vaccines. Applying lessons learned from COVID-19 therapeutic development to cancer immunotherapy clinical trials has the potential to greatly improve treatment options and outcomes for cancer patients. Therefore, the Committee urges the NCI to accelerate the translation of discoveries in cancer immunotherapy by means of the same innovations used to develop COVID-19 treatments and vaccines. This should include expediting consideration and support for potential high-impact cancer immunotherapy clinical trials, and for correlative science based on planned and ongoing clinical trials.